Abstract 603
Background
Observational studies show that Alzheimer’s disease (AD) and lung cancer is negatively associated in both directions. However, whether there is a causal relationship between AD and lung cancer remains uncertain. Mendelian Randomization (MR) is a novel approach for the assessment of causality, using genome-wide significant single-nucleotide polymorphisms (SNP) as instrument variables (IV) to eliminate the bias caused by confounders. In this study, we utilized a bi-directional two-sample MR analysis to estimate the potential causality between AD and lung cancer.
Methods
The genome-wide association study (GWAS) summary data of AD and lung cancer were derived from the International Genomics of Alzheimer’s Project (IGAP,17,008 AD cases and 37,154 controls) and the International Lung Cancer Consortium (ILCCO, 11,348 lung cancer cases and 15,861 controls), respectively. We performed a bi-directional two-sample MR analysis to determine the causal relationship between AD and lung cancer. To be specific, Inverse-Variance Weighted (IVW), MR-Egger and Weighted Median methods were utilized for deriving causal estimates. Single SNP analysis and leave-one-out analysis were also conducted to identify if a single SNP is driving the association. We also performed the MR-Egger regression and MR-PRESSO analysis for the evaluation of horizontal pleiotropy.
Results
There was no causal relationship between AD and lung cancer in bi-directional MR. The results of Single SNP analysis and leave-one-out analysis indicated that no single SNP was driving the association. No directional horizontal pleiotropy was detected in the MR-Egger regression analysis. The MR-PRESSO analysis did not detect horizontal pleiotropy. There was no evidence for violations of MR assumptions in the sensitivity analysis.Table:
1847P Mendelian randomization estimates of the causality
Exposure | Outcome | Inverse Variance Weighted | MR Egger | Weighted Median | |||
---|---|---|---|---|---|---|---|
OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value | ||
Alzheimer’s Disease | Lung Cancer | 1.040 (0.965-1.121) | 0.299 | 1.033 (0.890-1.199) | 0.676 | 0.999 (0.902-1.106) | 0.980 |
Lung Cancer | Alzheimer’s Disease | 0.919 (0.794-1.062) | 0.253 | 1.223 (0.597-2.504) | 0.637 | 0.920 (0.836-1.013) | 0.091 |
Conclusions
We found no causality between AD and lung cancer through the two-sample MR analysis. However, further study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract
3887 - First Real Life Data on Durvalumab after definitive concomitant ChemoRadiotherapy (cCRT) in unresectable Stage (St) III Non-Small Cell Lung Cancer (NSCLC) in France: Analysis of 591 patients (pts) enrolled in the French cohort (c) Temporary Authorization of Use (ATU)
Presenter: Virginie Avrillon
Session: Poster Display session 1
Resources:
Abstract
682 - EGFR Inhibitor Versus Chemotherapy as Adjuvant Treatment for Locally-advanced EGFR-mutant Non-Small Cell Lung Cancer
Presenter: Peng Xie
Session: Poster Display session 1
Resources:
Abstract
2509 - Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: interim analysis of a Phase IIIb, multi-national, open-label study
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3300 - First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Presenter: Daniel SW Tan
Session: Poster Display session 1
Resources:
Abstract
2653 - A combined analysis of two Phase IIIb studies of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo de Marinis
Session: Poster Display session 1
Resources:
Abstract
3663 - Impact of plasma EGFR mutation fractions on response to first generation tyrosine-kinase inhibitor in treatment of naïve non-small cell lung cancer patients
Presenter: Xiaohong Wang
Session: Poster Display session 1
Resources:
Abstract
5921 - Definition of an afatinib trough concentration threshold in the treatment of NSCLC
Presenter: Stephane Bouchet
Session: Poster Display session 1
Resources:
Abstract
2852 - A Phase Ib Trial of Neoadjuvant Chemoradiotherapy and Durvalumab(MEDI4736) for Potentially Resectable stage III Non-Small Cell Lung Cancer (NSCLC)
Presenter: Beung chul AHN
Session: Poster Display session 1
Resources:
Abstract
3273 - Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
Presenter: Jinsoo Lee
Session: Poster Display session 1
Resources:
Abstract